Grepafloxacin Clinical Program for Lower Respiratory Tract Infections
The present paper evaluates the clinical trial program in lower respiratory tract infections treated with a new fluoroquinolone antibiotic, grepafloxacin. Unlike older quinolones, grepafloxacin has excellent activity against Gram-positive organisms, which include Streptococcus pneumoniae and “atypic...
Saved in:
Main Author: | Arne C Rodloff |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
1998-01-01
|
Series: | Canadian Journal of Infectious Diseases |
Online Access: | http://dx.doi.org/10.1155/1998/762368 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibacterial Activity of Grepafloxacin
by: B Wiedemann, et al.
Published: (1998-01-01) -
The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children
by: Z Dangor, et al.
Published: (2024-11-01) -
Current Antibiotic Treatment and Outcome for Lower Respiratory Tract Infections
by: Alasdair P MacGowan, et al.
Published: (1998-01-01) -
Hypervirulent Klebsiella pneumoniae have better clinical outcomes than classical Klebsiella pneumoniae for lower respiratory tract infection patients
by: Xianxia Zhuo, et al.
Published: (2025-01-01) -
Correction: The salivary microbiota of patients with acute lower respiratory tract infection-A multicenter cohort study.
by: Matthew B Rogers, et al.
Published: (2025-01-01)